Von Hippel–Lindau diseaseTreatment options
A rare inherited condition that can cause tumors and cysts across several organs over a lifetime. Coordinated, lifelong surveillance and genetic counseling are the cornerstones of care.
Preview — not yet published
This page is in editorial and medical review. Content below is a scaffold — treat it as a preview, not guidance.
Common treatment routes in plain language. Your care team decides what fits you.
Before you read
This page describes common treatment routes so you can follow conversations with your care team. It is not personalized advice. Treatment choices depend on your specific diagnosis, overall health, and priorities — decisions your care team makes with you.
A reviewed summary of common treatment pathways will appear here once editorial and medical review are complete.
Review, sources, and disclaimer
How this page was reviewed
Pending medical review. This page will list the reviewing clinician and review date before publication.
Content version 0.1
- Von Hippel-Lindau Disease (PDQ®) — Health Professional Version· government
- Von Hippel-Lindau Syndrome — GeneReviews· other
- Von Hippel-Lindau syndrome — MedlinePlus Genetics· patient education
- FDA approval of Welireg (belzutifan) for VHL-associated tumors· government
- Guidelines for surveillance of patients with Von Hippel-Lindau disease· guideline
- VHL Handbook & Resources — VHL Alliance· patient education
This page is educational, not medical advice. Talk with your care team about decisions that apply to you. If something feels urgent, contact your doctor — or, for emergencies, call your local emergency number.